Total Payments
$3,703
2024 Payments
$163.96
Companies
32
Transactions
112
Medicare Patients
7,476
Medicare Billing
$866,666
Payment Breakdown by Category
Food & Beverage$2,357 (63.7%)
Other$1,000.00 (27.0%)
Education$346.18 (9.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,357 | 104 | 63.7% |
| Honoraria | $1,000 | 1 | 27.0% |
| Education | $346.18 | 7 | 9.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AltaThera Pharmaceuticals LLC | $1,000 | 1 | $0 (2020) |
| Horizon Therapeutics plc | $660.95 | 30 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $479.61 | 17 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $234.62 | 8 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $170.59 | 6 | $0 (2018) |
| CALLIDITAS THERAPEUTICS US INC. | $153.68 | 8 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $124.88 | 1 | $0 (2022) |
| Dova Pharmaceuticals | $109.07 | 1 | $0 (2020) |
| Amgen Inc. | $90.38 | 5 | $0 (2023) |
| Paratek Pharmaceuticals, Inc. | $72.17 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $163.96 | 7 | CALLIDITAS THERAPEUTICS US INC. ($61.67) |
| 2023 | $687.56 | 29 | Mallinckrodt Hospital Products Inc. ($280.26) |
| 2022 | $673.11 | 24 | Mallinckrodt Hospital Products Inc. ($147.43) |
| 2021 | $341.28 | 18 | Horizon Therapeutics plc ($181.61) |
| 2020 | $1,462 | 16 | AltaThera Pharmaceuticals LLC ($1,000) |
| 2019 | $16.77 | 1 | Amgen Inc. ($16.77) |
| 2018 | $60.96 | 4 | Relypsa, Inc. ($35.56) |
| 2017 | $297.42 | 13 | Alexion Pharmaceuticals, Inc. ($159.52) |
All Payment Transactions
112 individual payment records from CMS Open Payments — Page 3 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/13/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: ANTIBIOTIC | ||||||
| 06/28/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/21/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: Cardio-renal | ||||||
| 06/07/2022 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $8.55 | General |
| Category: IMMUNOLOGY | ||||||
| 03/08/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: KRYSTEXXA | ||||||
| 02/14/2022 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: Nephrology | ||||||
| 01/18/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.80 | General |
| 01/12/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: KRYSTEXXA | ||||||
| 01/11/2022 | Amgen Inc. | Tavneos (Drug) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: Not Applicable | ||||||
| 01/06/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.09 | General |
| 11/17/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: KRYSTEXXA | ||||||
| 11/08/2021 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: Neurology | ||||||
| 10/21/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: KRYSTEXXA | ||||||
| 10/12/2021 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/29/2021 | Merck Sharp & Dohme Corporation | DIFICID (Drug), RECARBRIO, ZINPLAVA | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/23/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: KRYSTEXXA | ||||||
| 09/21/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: Cardio-renal | ||||||
| 06/30/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: KRYSTEXXA | ||||||
| 05/27/2021 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/17/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: KRYSTEXXA | ||||||
| 05/04/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: KRYSTEXXA | ||||||
| 04/07/2021 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $28.66 | General |
| Category: Oncology | ||||||
| 04/05/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: KRYSTEXXA | ||||||
| 03/23/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: KRYSTEXXA | ||||||
| 02/23/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: KRYSTEXXA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 1,757 | 3,133 | $381,720 | $191,539 |
| 2022 | 30 | 1,859 | 3,389 | $433,530 | $220,232 |
| 2021 | 30 | 1,921 | 3,432 | $429,155 | $219,519 |
| 2020 | 33 | 1,939 | 3,455 | $455,715 | $235,375 |
Total Patients
7,476
Total Services
13,409
Medicare Billing
$866,666
Procedure Codes
123
All Medicare Procedures & Services
123 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 322 | 893 | $98,230 | $55,425 | 56.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 267 | 289 | $88,145 | $38,866 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 155 | 320 | $62,400 | $30,014 | 48.1% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2023 | 22 | 88 | $25,080 | $13,863 | 55.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 37 | 175 | $20,125 | $9,859 | 49.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 60 | 68 | $18,700 | $9,217 | 49.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 37 | 49 | $20,335 | $8,353 | 41.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 40 | 52 | $8,580 | $5,041 | 58.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 31 | 33 | $6,930 | $3,408 | 49.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 31 | $5,735 | $2,920 | 50.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $4,845 | $2,400 | 49.5% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 45 | 55 | $3,575 | $2,225 | 62.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 82 | 146 | $2,920 | $1,511 | 51.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 88 | 173 | $1,730 | $1,453 | 84.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $1,870 | $968.22 | 51.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 16 | 17 | $1,020 | $674.22 | 66.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 61 | 87 | $1,305 | $662.07 | 50.7% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 64 | 97 | $970.00 | $549.02 | 56.6% |
| 84100 | Phosphate level | Office | 2023 | 65 | 113 | $1,130 | $525.45 | 46.5% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 64 | 97 | $970.00 | $492.76 | 50.8% |
| 83021 | Hemoglobin analysis and measurement, chromatography | Office | 2023 | 21 | 26 | $780.00 | $460.20 | 59.0% |
| 82306 | Vitamin d-3 level | Office | 2023 | 14 | 15 | $675.00 | $435.15 | 64.5% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 21 | 26 | $780.00 | $427.96 | 54.9% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 25 | 30 | $750.00 | $393.60 | 52.5% |
| 84550 | Uric acid level, blood | Office | 2023 | 51 | 75 | $750.00 | $332.25 | 44.3% |
About Dr. Haroon Rashid, MD
Dr. Haroon Rashid, MD is a Nephrology healthcare provider based in Summerfield, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629006499.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Haroon Rashid, MD has received a total of $3,703 in payments from pharmaceutical and medical device companies, with $163.96 received in 2024. These payments were reported across 112 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($2,357).
As a Medicare-enrolled provider, Rashid has provided services to 7,476 Medicare beneficiaries, totaling 13,409 services with total Medicare billing of $866,666. Data is available for 4 years (2020–2023), covering 123 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Summerfield, FL
- Active Since 06/29/2006
- Last Updated 03/29/2019
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1629006499
Products in Payments
- Sotalol Hydrochloride (Drug) $1,000
- KRYSTEXXA (Biological) $614.70
- ACTHAR (Biological) $479.61
- SOLIRIS (Drug) $159.52
- TARPEYO (Drug) $153.68
- JARDIANCE (Drug) $124.88
- Doptelet (Drug) $109.07
- BRILINTA (Drug) $99.99
- LOKELMA (Drug) $92.17
- NUZYRA (Drug) $72.17
- JYNARQUE (Drug) $54.93
- TEPEZZA (Drug) $46.25
- Kerendia (Drug) $42.56
- GVOKE HYPOPEN (Drug) $36.92
- Veltassa (Drug) $35.56
- DIFICID (Drug) $35.29
- ORLADEYO (Drug) $34.91
- TRULICITY (Drug) $33.40
- Kyprolis (Drug) $28.66
- GATTEX (Drug) $27.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.